Lexicon Pharmaceuticals
LXRX
115 hedge funds and large institutions have $445M invested in Lexicon Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 31 increasing their positions, 32 reducing their positions, and 13 closing their positions.
100% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 13
88% more call options, than puts
Call options by funds: $1.74M | Put options by funds: $928K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
44% more capital invested
Capital invested by funds: $308M → $445M (+$136M)
12% more funds holding
Funds holding: 103 → 115 (+12)
4.47% more ownership
Funds ownership: 96.38% → 100.86% (+4.5%)
3% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$3.33M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$3.28M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$2.67M |
| 4 |
Bank of New York Mellon
New York
|
+$2.35M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.02M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$1.69M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.59M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$828K |
| 5 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
-$611K |
LXRX Hedge Fund Activity: Q4 2019 in Review
115 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q4 2019, worth a combined $445M — up 44% from $308M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new LXRX positions and 13 closed out — a net gain of 13 holders — while 31 added to existing stakes and 32 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $3.33M. The largest seller was Fidelity Investments, cutting an estimated $2.02M.
- 115 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q4 2019, up from 103 in Q3 2019.
- Funds reported $445M of Lexicon Pharmaceuticals stock for Q4 2019, up 44% quarter-over-quarter.
- 26 funds opened new Lexicon Pharmaceuticals positions in Q4 2019 and 13 closed out, a net change of +13 holders.
- The largest Lexicon Pharmaceuticals buyer in Q4 2019 was Two Sigma Investments, an estimated $3.33M added.
- The largest Lexicon Pharmaceuticals seller in Q4 2019 was Fidelity Investments, an estimated $2.02M sold.
Based on aggregated 13F filings for Q4 2019.